RecruitingNCT06587022
Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors
Sponsor
Peking University Third Hospital
Enrollment
500 participants
Start Date
Jan 1, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria3
- Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy;
- Patients with sufficent pre-treatment imaging data
- Patients who can cooperate with imaging review and follow-up after radiotherapy.
Exclusion Criteria4
- Patients with an expected survival of less than 3 months;
- Patients with second-course radiotherapy;
- Patients with physical conditions that cannot tolerate stereotactic radiotherapy;
- Patients with extensive spinal metastasis and no local therapeutic value
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RADIATIONTarget volume delineation
Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06587022
Related Trials
Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical
NCT052968894 locations
Clariance ErYs Registry
NCT051708151 location
Study of Olutasidenib and Temozolomide in HGG
NCT0616197418 locations
Evaluating the Efficacy and Safety of Intra-wound Vancomycin Powder in High Risk Patients
NCT038399141 location
Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases
NCT066132959 locations